At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...

WeDosify becomes CLM’s first commercially available product – delivering data-driven, adaptive dosing recommendations to improve GLP-1 adherence.Informed by 29 studies and 15,000+ patient profiles; ...

Health care professionals may prescribe GLP-1s for people with diabetes and binge eating disorder with strong psychotherapy support, a slow dose titration and close follow-up after initiation, ...

Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...

Ladies and gentlemen, greetings, and welcome to MBX Biosciences Conference Call. Today's call is being recorded. [Operator Instructions] As a reminder, this conference is being recorded. It is now my ...

In The Lancet Diabetes & Endocrinology, the STEP-UP T2D and STEP-UP trial groups present new findings on the efficacy and safety of higher-dose semaglutide (7·2 mg once weekly) in individuals with ...

A shortage of laboratories, equipment and chemicals continues to undermine student performance in science subjects across the ...

Bayer announced today that data from across the KERENDIA ® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s Annual Scientific ...

Tirzepatide may play a role in weight management in adults with T1D and obesity, even at low doses,” Jennifer R. Snaith, MD, ...

Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to ...

Lilly’s cardiovascular outcomes trial is the first to use an active comparator, finding noninferiority but not superiority of tirzepatide to dulaglutide in CV outcomes.